A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pre-treatment At the Time of Diagnosis in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI) - The ACCOAST Study - TADF
- Conditions
- Acute Coronary SyndromesMedDRA version: 14.1Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disorders
- Registration Number
- EUCTR2009-014176-22-SE
- Lead Sponsor
- Eli Lilly
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 4100
Inclusion Criteria
NSTEMI with elevated troponin
Scheduled for early coronary angiography and PCI
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
STEMI
Cardiogenic shock at time of randomisation
refractory ventricular arrhythmias
congestive heart failure
cardiac arrest
prior TIA or stroke
active pathological bleeding
severe hepatic impairment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Reduction in cardiovascular events NSTEMI patients undergoing PCI;Secondary Objective: Safety and net clinical benefit;Primary end point(s): Composite efficacy endpoint of cardiovascular events
- Secondary Outcome Measures
Name Time Method